p16INK4a/CDKN2A Antibody (1D7D2A1) - BSA Free

Western blot analysis using CDKN2A mouse mAb against Hela (1), HepG2 (2) and Hek293 (3) cell lysate.

Immunohistochemical analysis of paraffin-embedded endometrial cancer tissues using CDKN2A mouse mAb with DAB staining.

Flow cytometric analysis of Hela cells using CDKN2A mouse mAb (green) and negative control (red).

Western blot analysis using CDKN2A mAb against human CDKN2A (AA: 1-156) recombinant protein. (Expected MW is 19 kDa)

Western blot analysis using CDKN2A mAb against HEK293 (1) and CDKN2A (AA: 1-156)-hIgGFc transfected HEK293 (2) cell lysate.

Immunohistochemical analysis of paraffin-embedded esophageal cancer tissues using CDKN2A mouse mAb with DAB staining.

Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);

• Reactivity: Hu
• Applications: WB, ELISA, Flow, IHC, CyTOF-ready
• Clone: 1D7D2A1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

p16INK4a/CDKN2A Antibody (1D7D2A1) - BSA Free Summary

• Immunogen: Purified recombinant fragment of human p16INK4a/CDKN2A (AA: 1-156) expressed in E. Coli.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CDKN2A
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA 1:10000
  • Flow Cytometry 1:200 - 1:400
  • Immunohistochemistry 1:200 - 1:1000
  • Immunohistochemistry-Paraffin 1:200 - 1:1000
  • Western Blot 1:500 - 1:2000
• Application Notes: This antibody is Cytof ready.
• Theoretical MW: 16.5 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein G purified

Alternate Names for p16INK4a/CDKN2A Antibody (1D7D2A1) - BSA Free

• ARF
• CDK4 inhibitor p16-INK4
• CDK4I
• CDK4IP14ARF
• CDKN2
• CDKN2A
• cell cycle negative regulator beta
• CMM2P16-INK4A
• Cyclin-dependent kinase 4 inhibitor A
• cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
• cyclin-dependent kinase inhibitor 2A
• INK4
• INK4a
• MLM
• MLMP16INK4
• MTS-1
• MTS1P14
• Multiple tumor suppressor 1
• p14
• p14ARF
• p16
• p16-INK4
• p16INK4a
• p16-INK4a
• P19
• p19ARF
• TP16

Background

CDKN2A/p16INK4a is a gene that codes for a widely expressed protein with four isoforms, measuring 156, 105, 116, and 167 amino acids in length with weights of approximately 17, 11, 12, and 18 kDa respectively. CDKN2A/p16INK4a functions as a negative regulator of the proliferation of cells, which then allows them to interact with cyclins D and to phosphorylate the retinoblastoma protein. Current studies are being done on several diseases and disorders related to this gene including Li-Fraumeni syndrome, malignant peripheral nerve sheath tumor, blastic plasmacytoid dendritic cell, acth-secreting pituitary adenoma, recessive dystrophic epidermolysis bullosa, marginal zone b-cell lymphoma, adult astrocytic tumor, melanoma, and squamous cell carcinoma. CDKN2A/p16INK4a has also been shown to have interactions with MDM2, ZNF420, EGR1, MYCN, and CDK6 in pathways such as the cell cycle, p53 signaling, mitochondrial apoptosis, HIF-1 Alpha, CRHR, pancreatic cancer, and glioma pathways.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for p16INK4a/CDKN2A Antibody (NBP2-37736)(2)

Publications using NBP2-37736

• Al Shboul S, El-Sadoni M, Alhesa A et al. NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy Sci Rep 2023-09-23 [PMID: 37741850] (Immunohistochemistry, Human)
• Saleh T, El-Sadoni M, Alhesa A Et al. Expression of Senescence and Apoptosis Biomarkers in Synchronous Bilateral Breast Cancer: A Case Report Current oncology (Toronto, Ont.) 2021-09-30 [PMID: 34677245] (IF/IHC, Human)

FAQs for p16INK4a/CDKN2A Antibody (NBP2-37736). (Showing 1 - 1 of 1 FAQs).

1. Our customer asked us about NBP1-02905, which we lately found it discontinued. While checking its related products, there seems none. Would you please help confirm if there is any replacement available?
   • With regards to your question on our CDKN2A antibodies, we do supply a wide range of products, but you haven't specified which application you are referring to. Please go through this link (cyclin-dependent kinase inhibitor 2A) and choose the product that will suit your experiment and the species you are working with. Meanwhile it is important to keep in mind that CDKN2A generates several transcript variants which differ in their first exons.

Bioinformatics

• Gene Symbol: CDKN2A